Saving changes...

Done

Error

Expanding Horizons in Immuno-Oncology: Health System Pharmacists' Perspectives – Case 1: The New Immune Checkpoint Inhibitors: Toward a Cure for Metastatic Melanoma

Expanding Horizons in Immuno-Oncology: Health System Pharmacists' Perspectives – Case 1: The New Immune Checkpoint Inhibitors: Toward a Cure for Metastatic Melanoma

Expanding Horizons in Immuno-Oncology: Health System Pharmacists' Perspectives – Case 1: The New Immune Checkpoint Inhibitors: Toward a Cure for Metastatic Melanoma

Val R. Adams, PharmD,  FCCP, BCOP
Val R. Adams, PharmD, FCCP, BCOP
on behalf of Postgraduate Healthcare Education, LLC

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 13 Mar 2017
Expiry Date:

Last updated: 15 Mar 2017

Reference: 172103

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

In the past several years, the introduction of breakthrough therapies has revolutionized the treatment of patients with metastatic melanoma. These drugs work on T-lymphocytes to prevent 2 key immune checkpoints from blocking their actions. This learning initiative addresses this new class of treatment, which has been shown to dramatically improve both patient response and survival; this case activity will help guide pharmacists, especially those working in healthcare systems, to better treat patients with metastatic melanoma. A review of the emerging knowledge regarding the immunology of metastatic melanoma and the new immune checkpoints that have been developed, which enable the patient's immune system to overcome the normal inhibitory pathways that maintain self-tolerance, will be conducted. Key safety issues associated with these therapies will also be addressed. Ultimately, this module will help pharmacists to better understand their role in the treatment of patients with this serious, but now more treatable, cancer.

Objectives

Objectives
At the conclusion of this activity, the participant should be able to:

-Explain how the new checkpoint inhibitors offer an innovative approach to promoting an immune response in patients with metastatic melanoma.
-Assess the efficacy and safety of the several approved immunotherapeutics as mono- or combination-therapy regimens.
-Manage the specific immune-related toxicities associated with the use of anti-CTLA-4 and anti-PD-1 drugs.
Val R. Adams, PharmD,  FCCP, BCOP

Author Information Play Video Bio

Val R. Adams, PharmD, FCCP, BCOP
on behalf of Postgraduate Healthcare Education, LLC

Val R. Adams, PharmD, FCCP, BCOP Associate Professor Pharmacy Practice and Science Department College of Pharmacy University of Kentucky Lexington, Kentucky

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 0.50 Hours -
    Exam Pass Rate: 75
    -
    Reference: 0064-0000-16-210-H01-P

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error